

Woody International Publish Limited An Multidisciplinary Academic Journal Publisher

> Journal of Theory and Practice in Clinical Sciences, Volume 1, 2024 https://www.woodyinternational.com/

Safety and Effectiveness of Traditional Chinese Medicine Compound in Treating Idiopathic Membranous Nephropathy Network Meta-analysis

Jingxue Bai¹, Genping Lei^{2,*}, Yingying Sun³, Huijie Fu¹, Xian Lu¹, Dong Yang¹, Duo Deng¹

¹Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China

²Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, China

³Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning, China

*Author to whom correspondence should be addressed.

Abstract: Objective: To evaluate the clinical effectiveness and safety of different traditional Chinese medicine prescriptions combined with conventional western drugs to improve idiopathic membranous nephropathy (IMN) based on the Chinese medicine evidence system. METHODS: A computerized search of eight databases, including China Knowledge Network (CNKI), Wanfang, PubMed, and Web of Science, was conducted to collect randomized controlled trials (RCTs) of TCM compound formulas combined with conventional western medicines for the treatment of IMN, with a search timeframe of the period from the establishment of the database to 2023 October. The quality of the included literature was evaluated using the Cochrane Risk of Bias Assessment Tool version 2.0 (RoB2.0), reticulated Meta-analysis was performed using Stata 18.0 software, and the area under the cumulative ranking curve was used to rank the clinical efficacy and safety of the six interventions, with the aim of providing an evidence-based basis for the rational clinical selection of prescriptions for treating patients with IMN. RESULTS: Thirty-five RCTs involving 6 interventions and containing 2518 IMN patients were finally included. CONCLUSION: Thirty-five papers involving 2518 patients were finally included in the literature. The effect of the formula of tonifying deficiency and eliminating stasis + conventional western medicine was significant in lowering 24-hour urine protein quantification (SUCRA: 95.3%) and total cholesterol level (SUCRA: 98.2%); the formula of tonifying deficiency, eliminating stasis and dispelling dampness + conventional western medicine (SUCRA: 71.2%) was more effective in increasing the total effective rate; and the formula of tonifying deficiency, eliminating stasis and purging heat and dispelling dampness + conventional Western medicine was effective in lowering blood creatinine (SUCRA: 80.4%) and increased serum albumin level (SUCRA: 72.9%), while the formula for tonifying deficiency and clearing heat and dampness and conventional western medicine was more effective in lowering M-type phospholipase A2 receptor antibody titer (SUCRA: 86.0%). In terms of safety, the adverse effects of the TCM compound formula combined with conventional western drugs were overall less than those of conventional western drugs alone. The overall quality of the included RCTs was low, and more rigorous, large-sample size RCTs and basic studies are needed to verify the clinical applicability.

Keywords: Compound Chinese medicine; Idiopathic membranous nephropathy; Mesh Meta-analysis; 24hUTP; ALB; PLA2R; SCr; TC.

Cited as: Bai, J., Lei, G., Sun, Y., Fu, H., Lu, X., Yang, D., & Deng, D. Safety and Effectiveness of Traditional Chinese Medicine Compound in Treating Idiopathic Membranous Nephropathy Network Meta-analysis. *Journal of Theory and Practice in Clinical Sciences*, *1*, 32–49. Retrieved from https://woodyinternational.com/index.php/jtpcs/article/view/39.

1. Introduction

Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome, of which the unknown cause is called idiopathic membranous nephropathy (IMN), which is mainly characterised by the deposition of immune complexes in the subepithelial cells of the glomerular epithelial layer accompanied by a diffuse thickening of the glomerular basement membrane. The main characteristic. In the past decade, the incidence rate of IMN has been increasing year by year, up to 51.02% in some areas, and it has a tendency to exceed IgA nephropathy [1]. Although about 1/3 of patients with IMN go into spontaneous remission, in most cases the disease has a long course and complete cure is relatively difficult. Commonly used drugs include alkylating agents (cyclophosphamide), glucocorticoids, calcium-regulated neural phosphatase blockers (cyclosporine, tacrolimus), rituximab and other immunosuppressants to reduce urinary protein and protect renal function. However, long-term



This is an Open Access article distributed under the terms of the Creative Commons Attribution License <u>http://creativecommons.org/licenses/BY/4.0/</u> which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

use of these drugs may increase the risk of cancer, lead to electrolyte disorders, blood glucose abnormality, or damage to the liver and kidneys, and the price of some biologics is very high, which puts a certain degree of stress on the physical and mental health of patients with IMN. pressure on IMN patients both physically and mentally [2].

More and more studies have shown that traditional Chinese medicine can be used as a single alternative therapy or adjuvant therapy for IMN [3]. According to the recommendations of the Clinical Practice Guidelines for Traditional Chinese Medicine in Idiopathic Membranous Nephropathy (2021), low and intermediate-risk patients are recommended to combine the use of Chinese herbal medicine combinations or Chinese herbal medicine monomers on the basis of conventional immunosuppressive therapy, which can help to improve and prevent the patients' oedema, tiredness, secondary infections, thromboembolism, and many other clinical manifestations, and to improve the quality of survival [4]. Chinese medicine compound formulas are complicated and diverse, and the identification and treatment varies from person to person. Although the effects and efficacy of Chinese medicine compound formulas in combination with conventional western medicines have been reported in a large number of literatures, there is still a lack of direct comparisons between Chinese medicine compound formulas, as well as dosing regimens that can improve the clinical performance or specific indicators of patients with IMN. Therefore, in this study, the effects of Chinese medicine compound formulas combined with conventional western medicines were investigated through network Meta-analysis (NMA), and the results were presented in the following table [5], Different clinical indicators such as total clinical efficiency, 24 hours urinary protein excretion (24 hUTP), serum albumin (ALB), Anti Phospholipase A2 Receptor Antibody (PLA2RAb), serum creatinine (SCr), total cholesterol (TC), and total cholesterol (TC) were investigated in different Chinese herbal medicinal compound treatments. Receptor Antibody (PLA2RAb), serum creatinine (SCr), total cholesterol (TC) and other efficacies were compared and ranked horizontally, with the aim of arriving at the optimal formula of Chinese herbal medicine compounding, avoiding full-coverage and large cohort drug use by clinicians, and providing evidence-based medical evidence for the clinical treatment of IMN. The aim of this study is to provide evidence-based medical evidence for the clinical treatment of IMN.

2. Information and Methods

2.1 Study Registration

This study was registered in the International Prospective Registry for Systematic Evaluation database (PROSPERO) under the registration number CRD42023487080.

2.1.1 Study subjects

Patients with confirmed diagnosis of membranous nephropathy after renal puncture biopsy and excluding other secondary factors, race, gender and age are not limited [6].

2.1.2 Type of study

Randomised controlled trial (RCT) of TCM compounding for IMN (R conventional western medicine), language limited to Chinese or English.

2.1.3 Intervention

The control group used conventional western drugs, including conventional basic treatment (anticoagulation, diuretic, antihypertensive, protein-lowering, lipid-lowering, etc.) and IMN general regimen treatment, such as glucocorticoids, immunosuppressants (tacrolimus, cyclosporine, cyclophosphamide, mycophenolate mofetil, etc.), angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, biologics (rituximab) and so on. The experimental group used conventional western medicines in combination with Chinese herbal medicine compounding.

2.1.4 Outcome indicators

(1) Overall clinical effectiveness rate Refer to the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines 2021: complete clinical remission of IMN is defined as urinary protein <0.3g/d and serum albumin \geq 3.5g/dL, partial remission is defined as \geq 50% reduction in urinary protein and final urinary protein of

0.3-3.5 g/d. Overall effective rate = (number of cases in complete remission + number of cases in partial remission)/(total number of cases × 100%) [7]; ② 24hUTP; ③ ALB; ④ SCr; ⑤ PLAR2; ⑥ TC; ⑦ 不良反应.

2.2 Exclusion Criteria

Interventions that used TCM therapies other than TCM compounding; more than one type of TCM preparation; no control group, or poor trial design, or inappropriate statistical methods; studies with less than 8 weeks of clinical efficacy observation; self-control studies; literature with obvious errors in the data; literature with no access to the full text; and literature with less than 2 articles of the same type of intervention.

2.3 Search Strategy

Computer searches were performed on databases such as China Knowledge (CNKI), Wanfang (Wanfang), Vip (VIP), SinoMed, PubMed, EMbase, Cochrane Library, MEDLINE, Web of Science, and so on, to search for the literature from the establishment of the database to October 2023. The search was conducted using a combination of subject terms and free words, and the Chinese search terms included "idiopathic membranous nephropathy", "primary membranous nephropathy", "traditional Chinese medicine", "Chinese medicine", "andomised controlled", "randomised Randomised controlled" "Randomised clinical trial", etc. The search terms in English include "Glomerulonephropathy, Membranouss" "Idiopathic Membranous Glomerulonephritis" "Glomerulonephritides, Idiopathic Membranous" "Chinese medicine", "traditional chinese medicine" "randomised clinical controlled trial" "conventional western medicine", etc.

2.4 Literature Screening and Data Extraction

Two researchers imported the results of literature search into Endnote X9 software, which removed duplicates and then further read the titles and abstracts, and screened them according to the inclusion and exclusion criteria. Excel software was used to extract information on authors, year of publication, sample size, mean age, interventions, duration of treatment, and outcome indicators. If there was disagreement it was discussed or adjudicated by a third researcher.

2.5 Methods for Evaluating the Quality of Literature

Two researchers followed the preset criteria to evaluate the quality of the included literature using the Cochrane Risk of Bias Assessment Tool version 2.0 (RoB2.0) separately, evaluating the 5 dimensions of bias: randomised methods, interventions, missing data ($\leq 10\%$ of the total number of cases), outcome measures and selective reporting[8].The results were categorised as low risk, high risk and uncertain risk, and any disagreements were discussed and resolved by negotiation or adjudicated by a third researcher.

2.6 Statistical Analyses

This study used Stata 18.0 software for statistical analysis, and relative risk (RR) was used for dichotomous variable effects, and weight mean difference (WMD) was used for continuous variable effects, and 95% credibility intervals (CI) were calculated respectively. The 95% confidence intervals (CI) were calculated separately. If there was good homogeneity among the studies, the analysis was performed using a random-effects model; if there was heterogeneity among the studies (I2 > 50% or P < 0.05), further subgroup analyses were performed. Network evidence maps for each outcome indicator were plotted sequentially, publication bias was assessed using a corrected-funnel plot, and rank probability plots were produced using the area of the curve under the Cumulative Ranking of Probabilities (Sur Face Under the Cumulative Ranking Curveweight mean difference, WMDSUCRA) to rank the clinical efficacy of different interventions. Corrected-comparison funnel plots were used to detect publication bias, which was verified using Egger's test, and if bias existed, the impact of bias on the results was assessed using the cut-and-patch method.

3. Results

3.1 Basic Characteristics of the Included Literature

According to the PICOS search strategy, the search was carried out in accordance with the search method of subject words + free words. The preliminary search obtained 1736 pieces of literature, and 35 pieces of literature were finally included, of which 33 were in Chinese [9-41], 2 in English [42,43]. The total sample size was 2518 cases, 1267 cases in the test group and 1251 cases in the control group. The interventions were divided into 5 categories: 5 articles of formulae for tonifying deficiency + conventional western medicine (X + conventional western medicine); 9 articles of formulae for tonifying deficiency and eliminating blood stasis + conventional western medicine (XY + conventional western medicine (XRS + conventional western medicine); 11 articles of formulae for tonifying deficiency and eliminating blood stasis and dispelling dampness + conventional Western medicine (XYS + conventional Western medicine); and 8 articles of formulae for tonifying deficiency, eliminating blood stasis and clearing heat and dispelling dampness + conventional Western medicine (XYS + conventional Western medicine); and 8 articles of formulae for tonifying deficiency, eliminating blood stasis and clearing heat and dispelling dampness + conventional Western medicine (XRSY +). (XRSY + conventional western medicine) 8 articles [13,19,20,25,29,36,38,42]. The literature screening process is shown in Figure 1 and the basic characteristics of the included literature are shown in Table 1.




Figure 1	l: .	Article	screening	process

Author/year	Sample siz (male/female)		Mean age/(years)		Mean age/(years)		Intervention		Course	Outcome indicator
	С	Т	С	Т	-					
Xing Yang 2023	28(21/7)	29(20/9)	53.96±9.24	54.66±10.06	Jiawei Zhenwu Tang + CT		8 weeks	1235 67		
Zhen Cai 2 019	26(-)	32(-)	44.32±13.32	42.26±13.26	Radix Astragali Di Huang Tang + CT		24 weeks	1236		
Lei Wang 2 020	26(-)	28(-)	46.6±12.9	47.6±13.2	Radix Astragali Di Huang Tang + CT	X+CT	24 weeks	1236		
Chao Song 2020	30(22/8)	30(21/7)	47.90±11.43	45.33±9.97	Warming Yang and Lifting Wat er Formula +CT		3 month s	1234 567		
Ling Huang 2023	33(17/16)	34(18/16)	51.48±7.31	52.41±6.41	Yiyuanjianzhong Formula+CT		9 month s	1234 567		
Jieqi Zheng 2019	39(22/17)	38(20/18)	51.8±17.88	54.53±5.39	Zhen Wu Tang with Angelica Si nensis and Paeoniae Alba+CT	XY+ CT	8 weeks	1234 567		

Table 1:	Basic	charac	eteristics	of	included	literature

Xueyan Su n 2022	39(21/18)	42(22/20)	58.05±12.27	57.14±13.92	Benefiting Qi, Nourishing Kidne y and Promoting Blood+CT		6 month s	$ \begin{array}{c} 1234 \\ 67 \end{array} $
Xin Feng 2 021	36(20/16)	36(2	2/14)	-	Benefiting Qi and Eliminating C rimes+CT		6 month s	6 months
Yating Zha ng 2022	39(26/13)	39(26/13)	52.53+11.69	50.97+10.42	Radix Astragali Di Huang Tang +CT	Radix Astrag	6 month s	$ \begin{array}{c} 1234 \\ 67 \end{array} $
Guojun Tan g 2020	34(16/18)	33(1	8/15)	-	Qi Jishen combined with Taoh ong Siwu Decoction + CT	ali, Ra dix et	3 month s	3 months
Chongxia Z hao 2022	43(31/12)	43(30/13)	51.24±3.26	51.12±3.21	Add flavour to tonify Yang and r estore the five elements+CT	Rhizo ma Gi	6 month s	1246
Xue Li 202 2	25(14/11)	25(18/7)	57.12±12.54	55.61±9.52	Invigorate Blood and Promote Water Formula + CT	nseng, Radix	6 month s	1234 567
Changan C hen 2022	28(17/11)	28(15/13)	58.54±8.34	62.11±9.60	Tonifying Qi and Benefiting Kid ney Formula + CT	et Rhiz oma P olygon	6 month s	1236 7
Jiajiao Zuo 2018	80(47/	/33)	Averag	ge age 48	Qiling Tongluo Prescription + CT	i Multi flori+ CT	6 month s	1234 57
Zhou Shi 2 022	40(22/18)	40(25/15)	57.38±12.35	57.90±13.14	Benefiting Qi, Tonifying the K idneys and Clearing the Profit Formula + CT	XSR+	12 wee ks	$ \begin{array}{c} 1234 \\ 567 \end{array} $
Jia Liu 202 1	24(15/9)	28(18/10)	55.35±10.65	55.75±11.081	Strengthening the spleen, benefiting the kidneys, clearing heat and inducing dampness formul a + CT	CT	12 wee ks	1236 7
Yun Ma 20 23	26(-)	27(-)	47.56±14.03	45.32±12.15	Warming Yang and Clearin g Dampness Formula + CT		24 wee ks	$\begin{array}{c} 1234 \\ 67 \end{array}$
Jie Li 2020	6038/22	60(35/25)	44.83±10.56	45.23±10.07	Wen Yang Dispels Dampne ss and Circulates Dampness Formula + CT		6 month s	$ \begin{array}{r} 1234 \\ 567 \end{array} $
Yanan Zha ng 2023	33(22/11)	34(23/11)	43.58±11.45	42.47±10.98	Wen Yang Dispels Dampne ss and Circulates Dampness Formula + CT		6 month s	1234 567
Qiang Liu 2 019	39(-)	39(-)	17.70±6.71	19.22±7.45	Warming Yang, Promoting Blood and Lifting Water+C T		48 wee ks	$1234 \\ 567$
Zheng Zha ng 2022	28(14/11)	25(13/12)	54.28±10.84	54.45±10.28	Jin Qi Benefit Kidney Form ula+CT	XSY+	6 month s	$1234 \\ 567$
Kexin Wan g 2022	30(18/12)	30(17/13)	42.31±8.05	41.63±7.31	Ginseng Astragali and Dihu ang Tang+CT	СТ	6 month s	$1234 \\ 567$
Jianjun Guo 2022	46(30/16)	46(26/20)	45.67±13.45	49.79±12.50	Strengthening the spleen an d dispelling dampness+CT		3 month s	$ \begin{array}{c} 1234 \\ 67 \end{array} $
Meng Ji 20 21	28(20/8)	30(18/12)	48.1±8.8	49±9.0	Kun Xian Capsule±CT		6 month s	1237
Jie Liu 202 2	30(18/12)	30(16/14)	48.59±4.63	49.14±4.76	Rhizoma Ligustici Tongluo Capsule+CT		6 month s	$ \begin{array}{c} 1234 \\ 67 \end{array} $
Wu 2022	42(29/13)	42(31/11)	8.50±1.60	8.26±1.71	Strengthening the Spleen, D ispelling Dampness and He patoconjugate Formula+CT		2 month s	$\begin{array}{c} 1234 \\ 67 \end{array}$
Leilei He 2 022	84(45/39)	84(47/37)	54.56±5.03	53.96±5.12	Kidney Yikang+CT		3 month s	167
Genping Le i 2019	30(19/11)	29(19/10)	48.97±11.61	51.69±11.31	Astragalus Di-Fixing Kidne y Tablet+CT		6 month s	$ \begin{array}{r} 1234 \\ 567 \end{array} $
Huaxia Liu 2019	29(19/10)	29(17/12)	46.34±14.38	47.41±13.60	Tonifying the Kidneys, Res olving Blood Stasis and Cle aring Drainage Formula + C T		6 month s	1234 567
Lina Qiao 2 020	29(16/13)	30(18/12)	43.07±9.083	47.27±9.938	Tonifying Qi, Resolving Da mpness and Clearing Draina ge+CT		8 weeks	$ \begin{array}{r} 1234 \\ 567 \end{array} $
Jin Wu 202 1	49(27/22)	49(26/23)	53.69±3.63	52.38±3.76	Radix Astragali and Radix Rehmanniae Formula+CT	XSR Y+CT	6 month s	1234 56
Rong Zhao 2021	22(16/6)	22(14/8)	50.07±14.17	50.37±11.99	Huangtu Yi Kidney Granule s+CT		6 month s	1234 567
Gaohua Pin g 2021	35(19/16)	35(20/15)	44.1±10.2	8.9±4.2	Clearing and Resolving Tur bidities Capsule+CT		16 wee ks	234
Yaping Gu o 2021	42(12/30)	42(13/29)	46.96±8.63	48.21±7.57	Qi Di Tao Hirch Er Cicada Formula+CT		3 month	1235
Lv W2021	42(38/4)	42(30/12)	61.56±7.11	62.01±6.89	Nephritis Rehabilitation Ta blets+CT		12 wee ks	1237

Notes: T. Test group; C. Control group; -. Conventional Western medicine; control group interventions were all conventional Western medicine; ① total effective r ate; ② 24hUTP; ③ ALB; ④ Scr; ⑤ TC; ⑥ PLAR2; ⑦ adverse reactions; ⑧ X + CT. Regular formulae and western herbal remedies for tonifying deficiency, el iminating stasis and dispelling dampness; XRSY+CT.

3.2 Evaluation of the Quality of the Literature

Evaluation of randomisation methods included interventions, error in outcome data ($\leq 10\%$ of total cases), outcome measures, selective reporting and methodological aspects of random sequence generation 25 RCTs [9-13,15,16,18,20-23,25,26,28,30-33,35,36,39-41,43] 1 article by random number table method [14] Low risk based on random allocation; 8 articles[19,24,27,29,34,37,38,42]Mention of the word random only, 1 article [17] Grouping according to chronological order of admission was risk uncertain. For interventions and outcome measures, all studies did not mention the allocation of concealment programmes and the use of blinding by the investigator, subjects or outcome measures, as risk uncertain. For completeness of outcome data, 17 [13,15-18,24-27,30,36,38-43] Subjects were not dislodged in the RCTs, which is low risk; 17 articles [9-12,14,18-20,23,28,29,31-35,37] Subjects with a shedding rate of less than 10 per cent are at low risk; 1 article [21] Subjects with a shedding rate greater than 10% are at high risk. For selective reporting, 1 [40] The possibility of selective reporting was high risk, while no selective reporting was found in the remaining 34 papers, which was low risk. The results of literature quality evaluation are shown in Figure 2.




Figure 2: Proportion of items of included articles that produced risk of bias

3.3 Traditional Meta-analysis

Traditional Meta-analysis reported the total effective rate (31 RCTs), 24 hUTP (34 RCTs), ALB (32 RCTs), PLA2R (25 RCTs), SCr (23 RCTs), and TC (21 RCTs), respectively, and the fixed-effects model or the randomeffects model was used according to the size of the I² between studies of the same intervention, respectively. The results were analysed and showed that in terms of total effective rate, 24 hUTP and ALB, the therapeutic measures of TCM compound combined with conventional western drugs were superior to conventional western drugs alone, and the differences were statistically significant (P<0.05), as shown in Table 2 (below). In addition, the conventional Meta-analysis in PLA2R, SCr and TC showed that, except for the formula for tonifying deficiency, clearing heat and dispelling dampness + conventional western medicine WMD=-20.353, 95% CI [-49.047, 8.340] in PLA2R, the formula for tonifying deficiency, clearing heat and dispelling dampness + conventional western medicine in TC (WMD=-0.610, 95% CI [-6.011, 4.791]), and the three interventions of the formula for tonifying deficiency and clearing heat and dampness in TC + conventional western medicine (WMD=-1.015, 95% CI [-6.039, 4.010]), the rest of the results could confirm the superiority of the effect of Chinese herbal medicine compounding in combination with conventional western medicine over the conventional western medicine alone, and the difference was statistically significant (P<0.05).

Table 2: Traditional Meta-analysis of each outcome indicator									
		Total effectiveness ra	te		24UTP			ALB	
Intervention	RCT	RR(95%CI)	Î	RCT	WMD(95%CI)	Î	RCT	WMD(95%CI)	f
V. OT	4	1.348 *	0.00%	5	-0.502 *	0.00%	5	2.229*	22.40%
X+CT	CT 4 0.00% 5 (-0.577,-0.428)	0.00%	Э	(1.255,3.204)	23.40%				
XX. CT	0	1.338 *	0.00%	0	-1.414 *	04.40%	8	2.8269*	0.00%
XY+CT	CT 8 0.00% 9 (-2.124,-0.705)	94.40%	8	(2.310,3.341)	0.00%				
VCV. CT	0	1.271 *	3) 16.30%	10	-1.022*	96.60%	9	3.810*	90.30%
XSY+CT	9	(1.176,1.373)		6 10	(-1.387,-0.657)	90.00%	9	(2.365,5.255)	

XSR+CT	2	1.410 * (1.068,1.862)	0.00%	2	-0.592* (-0.885,-0.300)	0.00%	2	3.663* (1.302,6.024)	78.10%
XSRY+CT	8	1.235 * (1.137,1.341)	0.00%	8	-0.731* (-1.074,-0.388)	78.40%	8	4.336* (3.075,5.598)	64.10%
		PLA2R			SCr			тс	
Intervention	RCT	WMD (95%CI)	f	RCT	WMD (95%CI)	f	RCT	WMD (95%CI)	f
X+CT	5	-13.381* (-24.315,-2.448)	88.20%	2	-1.015 (-6.039,4.010)	0.00%	3	-0.342 * (-0.619,0.066)	19.80%
XY+CT	6	-27.027* (-42.059,11.995)	96.50%	7	-6.592 * (-9.875,-3.308)	54.50%	5	-1.513 * (-2.226,0.800)	88.20%
XSY+CT	7	-10.233* (-14.334,-6.131)	87.60%	6	-6.383 * (-10.949,-1.818)	93.30%	7	-0.603* (-1.068,0.138)	96.20%
XSR+CT	2	-20.353 (-49.047,8.340)	58.20%	2	-0.610 (-6.011,4.791)	-	1	_	-
XSRY+CT	5	-6.705* (-8.490,-4.920)	0.00%	6	-7.653 * (-14.567,-0.739)	89.60%	5	-0.252* (-0.368,0.136)	13.20%

3.4 Network Meta-analysis

In this study, an evidence network diagram was produced for each outcome indicator, with the size of the dots representing the size of the sample size, and the thickness of the line representing the size of the standard error, and no closed loops were formed between the interventions, so there was no need for inconsistency testing, and the results are shown in Figure 3. The relative effect values of the results of the two-by-two comparisons of the six interventions are shown in Figure 4. Based on the SUCRA values of each intervention, a rank probability plot was drawn to more intuitively rank the cumulative probability of each intervention in terms of its superiority or inferiority, as shown in Figure




Figure 3: The Evidence network diagram

3.4.1 Total effectiveness rate

31RCTs [9-13,16,17,19-29,31-43] used overall effectiveness as the primary outcome metric of the study and included a total of 2195 patients. The evidence network showed that: six interventions, a total of 15 directly comparable outcomes were formed. Net Meta-analysis showed that: tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine (RR=1.03, 95% CI [0.55, 1.93]), tonifying

deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine (RR=3.28, 95% CI [2.03, 5.29]), tonifying deficiency class formula + conventional western medicine RR=3.10 (95% CI [1.67, 5.76]), and tonifying deficiency and elimination of blood stasis and clearing heat and dampness category formula + conventional western medicine (RR=1.17, 95% CI [0.51, 2.69]), deficiency tonifying and elimination of blood stasis category formula + conventional western medicine alone, with a statistically significant difference (P<0.05). The difference between the two-by-two comparisons of the remaining types of interventions was not statistically significant. According to the rank probability plot, the interventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and dispelling dampness class formula + conventional western medicine > tonif

3.4.2 24hUTP

34RCTs [9-39,41-43] reported on 24 hUTP and included a total of 2350 patients. The evidence network showed that: six interventions with a total of 15 directly comparable outcomes were formed. Net Meta-analysis showed that compared with conventional western medicine alone, the formula for tonifying deficiency and eliminating stasis + conventional western medicine (WMD = -1.48, 95% CI [-1.93, -1.04]), the formula for tonifying deficiency and eliminating stasis and expelling dampness + conventional western medicine (WMD = -1.13, 95% CI [-1.53, -0.74]) and the formula for tonifying deficiency + conventional western medicine (WMD = -0.93, the 95% CI [-1.50, -0.36]) were both more effective than conventional western medicine alone in reducing 24 hUTP, in addition, compared to the formula for tonifying deficiency and eliminating stasis, clearing heat and dispelling dampness class formula + conventional western medicine, the formula for tonifying deficiency and eliminating stasis class formula + conventional western medicine (WMD = -1.00, 95% CI [-1.65, -0.35]) and the formula for tonifying deficiency and eliminating stasis, dispelling dampness class formula + conventional western medicine (WMD = -0.65, 95% CI [-1.27, -0.03]) had better clinical efficacy, and the rest of the differences between the two were not statistically significant. According to the rank probability plot, the interventions were ranked as tonifying deficiency and eliminating blood stasis class formula + conventional western medicine > tonifying deficiency and eliminating blood stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency and eliminating heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency and eliminating blood stasis and dispelling heat and dispelling dampness class formula + conventional western medicine > conventional western medicine. The calibration-comparison funnel plot showed general symmetry, with some studies distributed outside the 95% CI, and Egger's test p=0.166, suggesting no significant publication bias (p>0.05).

Translated with www.DeepL.com/Translator (free version)

3.4.3 ALB

32RCTs [9-14,16-25,27-39,41-43] reported on ALB and included a total of 2214 patients. The evidence network showed that the six interventions yielded a total of 15 two-by-two directly comparable outcomes. Net Metaanalysis showed that, compared with conventional western medicine alone, the formula for tonifying deficiency, eliminating stasis, clearing heat and dispelling dampness + conventional western medicine (WMD = 4.12, 95% CI [2.59, 5.65]), the formula for tonifying deficiency, eliminating stasis and dispelling dampness + conventional western medicine (WMD = 3.96, 95% CI [2.51, 5.41]), the formula for tonifying deficiency, eliminating stasis and dispelling dampness + conventional Western medicine (WMD = 3.91, 95% CI [2.36, 5.45]), and the formula for tonifying deficiency and clearing heat and dampness + conventional western medicine were superior to conventional western medicine alone, and the rest of the differences between the two comparisons were not statistically significant. According to the rank probability plot, the interventional western medicine > tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency clearing heat and dispelling dampness class formula + conventional western medicine showed general symmetry, with some studies distributed outside the 95% CI, and Egger's test p=0.82, suggesting no significant publication bias (p>0.05).

3.4.4 PLA2RAb

25RCTs [9-14,16-31,33-35] reported on PLA2R and included a total of 1663 patients. The evidence network showed that the 6 interventions vielded a total of 15 directly comparable outcomes. Net Meta-analysis showed that the combination of only two formulas, namely the formula for tonifying deficiency + conventional western medicine (WMD=-40.26, 95% CI [-69.41, -11.11]) and the formula for tonifying deficiency and eliminating blood stasis + conventional western medicine (WMD=-26.47, 95% CI [-49.59, -3.34]), was more effective than the combination of conventional western medicine alone, and the difference was statistically significant (P < 0.05). The rest of the two-by-two comparison differences were not statistically significant. According to the rank probability plot, the interventions were ranked as formula for tonifying deficiency + conventional western medicine > formula for tonifying deficiency and eliminating blood stasis + conventional western medicine > formula for tonifying deficiency and clearing heat and dispelling dampness + conventional western medicine > formula for tonifying deficiency and eliminating blood stasis and dispelling dampness + conventional western medicine > formula for tonifying deficiency and eliminating blood stasis and clearing heat and dispelling dampness + conventional western medicine > conventional western medicine. The calibration-comparison funnel plot showed that the symmetry was fair, and some studies were distributed outside the 95% CI, and the Egger's test p=0.005 suggested the existence of publication bias, and the clipping method was repeated to evaluate the effect of publication bias on the results, and the clipping method results showed that 0 clippings occurred, and 0 negative papers were included additionally, which, combined with the results of the Egger's test, indicated that the possibility of publication bias was small.

3.4.5 SCr

23RCTs [12-17,19-21,23,25-27,29-34,36,39,41,42] reported on SCr and included a total of 1582 patients. The evidence network showed that the six interventions produced a total of 15 directly comparable outcomes. Net Meta-analysis showed that only the formula of tonifying deficiency, eliminating stasis, clearing heat and dispelling dampness + conventional western medicines (WMD=-7.86, 95% CI [-13.53, -2.18]) and the formula of tonifying deficiency, eliminating stasis and dispelling dampness + conventional western medicines (WMD=-6.41, 95% CI [-12.42, -0.40]) were more effective than conventional western medicines alone in lowering the SCr, and the difference was statistically significant (P<0.05), and the rest of the two-by-two comparisons were not statistically significant. According to the rank probability plot, the interventions were ranked as tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency, eliminating stasis and clearing heat and dispelling dampness class formula + conventional western medicine > tonifying

3.4.6TC

21RCTs [9,12-14,16,17,9,20,22-24,26,27,29,31,33,35,38-40,43] reviewed SCr and included a total of 1538 patients. The evidence network showed that: the 6 interventions yielded a total of 15 directly comparable outcomes. Net Meta-analysis showed that, compared with the application of conventional western medicine alone, the formula for tonifying deficiency + conventional western medicine (WMD=-1.52, piecewise 95% CI [-2.03, -1.00]) and the formula for tonifying deficiency, eliminating stasis, and dispelling dampness + conventional western medicine (WMD=-0.66, 95% CI [-1.07, -0.24]) were able to reduce TC more than the application of conventional western medicine alone, and, between the two, the formula for tonifying deficiency, eliminating stasis, and dispelling dampness + conventional Western medicine WMD=-1.32, 95% CI [-2.15, -0.50] was more effective, and the difference was statistically significant (P<0.05). In addition, the clinical efficacy of the formula for tonifying deficiency and eliminating blood stasis to improve TC was better than that of the formula for tonifying deficiency and eliminating blood stasis to clear heat and dispel dampness + conventional western medicine (WMD=-1.28, 95% CI [-2.00, -0.57]) and the formula for tonifying deficiency and eliminating blood stasis to clear heat and dispel dampness + conventional western medicine (WMD=-1.28, 95% CI [-2.00, -0.57]) and the formula for tonifying deficiency and eliminating blood stasis to the two two-measure comparisons did not have a statistically significant difference. According to the rank probability plot,

Bai, J., Lei, G., Sun, Y., Fu, H., Lu, X., Yang, D., & Deng, D. Journal of Theory and Practice in Clinical Sciences, 1, 32-49.

the interventions were ranked as tonifying deficiency and eliminating stasis class formula + conventional western medicine > tonifying deficiency and eliminating stasis and dispelling dampness class formula + conventional western medicine > tonifying deficiency and eliminating heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency and eliminating stasis and dispelling heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency and eliminating stasis and dispelling heat and dispelling dampness class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine > tonifying deficiency class formula + conventional western medicine. The calibration-comparison funnel plot showed poor symmetry, with some studies distributed outside the 95% CI, and Egger's test p=0.061, suggesting no significant publication bias (p>0.05).

a.	XSR+CT			RR(95%CI)		
	1.03(0.55,1.93)	XSY+CT				
	1.09(0.52,2.29)	1.06(0.48,2.31)	X+CT		•	
	1.15(0.65,2.02)	1.11(0.60,2.07)	1.05(0.50,2.19)	XSRY+CT		
	1.34(0.58,3.09)	1.29(0.54,3.11)	1.22(0.47,3.20)	1.17(0.51,2.69)	XY+CT	
b.	3.39(2.26,5.08)	3.28(2.03,5.29)	3.10(1.67,5.76)	2.96(1.98,4.41)	2.53(1.22,5.28)	СТ
	XY+CT			RR(95%CI)		
	-0.35 (-0.95,0.25)	XSY+CT				
	-0.55 (-1.27,0.17)	-0.20 (-0.89,0.49)	X+CT			
	-0.91 (-1.90,0.09)	-0.56 (-1.53,0.42)	-0.36 (-1.41,0.70)	XSR+CT		
	-1.00 (-1.65,-0.35)	-0.65 (-1.27,-0.03)	-0.45 (-1.19,0.29)	-0.09 (-1.10,0.92)	XSRY+CT	
	-1.48 (-1.93,-1.04)	-1.13 (-1.53,-0.74)	-0.93 (-1.50,-0.36)	-0.58 (-1.47,0.31)	2.53 (1.22,5.28)	СТ
c.	XSRY+CT			RR(95%CI)		
	0.16 (-1.95,2.26)	XSY+CT				
	0.21 (-1.96,2.38)	0.05 (-2.06,2.17)	XY+CT			
	0.62 (-2.79,4.03)	0.46 (-2.91,3.83)	0.41 (-3.00,3.82)	XSR+CT		
	1.48 (-1.01,3.97)	1.32 (-1.12,3.76)	1.27 (-1.22,3.76)	0.86 (-2.76,4.48)	X+CT	
	4.12 (2.59,5.65)	3.96 (2.51,5.41)	3.91 (2.36,5.45)	3.50 (0.45,6.54)	2.64 (0.68,4.60)	СТ
d.	X+CT			RR(95%CI)		
	-13.79 (-50.90,23.31)	XY+CT				
	-12.91 (-60.01,34.18)	0.88 (-42.87,44.63)	XSR+CT	-		
	-23.99 (-59.06,11.07)	-10.20 (-40.56,20.16)	-11.08 (-53.11,30.95)	XSY+CT		
	-27.12 (-66.26,12.01)	-13.33 (-49.05,22.39)	-14.21 (-60.25,31.83)	-3.13 (-36.72,30.47)	XSRY+CT	
	-40.26 (-69.41,-11.11)	-26.47 (-49.59,-3.34)	-27.35 (-64.50,9.80)	-16.27 (-35.94,3.41)	-13.14 (-40.42,14.14)	СТ
e.	XSRY+CT			RR(95%CI)		
	-1.45 (-9.72,6.82)	XSY+CT				
	-3.92 (-11.87,4.02)	-2.47 (-10.66,5.72)	XY+CT			
	-4.68 (-16.48,7.11)	-3.23 (-15.20,8.73)	-0.76 (-12.50,10.98)	X+CT		
	-7.34 (-23.18,8.50)	-5.89 (-21.85,10.08)	-3.41 (-19.21,12.38)	-2.65 (-20.70,15.39)	XSR+CT	
	-7.86 (-13.53,-2.18)	-6.41 (-12.42,-0.40)	-3.93 (-9.49,1.62)	-3.17 (-13.51,7.17)	-0.52 (-15.31,14.27)	СТ
f.	XY+CT			RR(95%CI)		
	-0.86 (-1.52,-0.20)	XSY+CT				
	-0.90 (-2.14,0.35)	-0.04 (-1.24,1.17)	XSR+CT			
	-1.28 (-2.00,-0.57)	-0.42 (-1.07,0.22)	-0.39 (-1.62,0.85)	XSRY+CT		
	-1.32 (-2.15,-0.50)	-0.46 (-1.23,0.31)	-0.43 (-1.73,0.88)	-0.04 (-0.85,0.77)	X+CT	
	-1.52 (-2.03,-1.00)	-0.66 (-1.07,-0.24)	-0.62 (-1.75,0.51)	-0.23 (-0.73,0.26)	-0.19 (-0.84,0.45)	СТ

Figure 4: Relative effect analysis of outcomes.

green. Interventions; yellow. Indicating statistical significance




Figure 5: Rank probability of each outcome indicator

3.5 Publication Bias Detection

As shown in Figure 6, we plotted a corrected-comparison funnel plot for all outcomes to assess potential publication bias. In Egger's test, p = 0.962 for total clinical effectiveness, p = 0.166 for 24h UTP reduction, p = 0.82 for ALB increase, p = 0.521 for SCr decrease, and p = 0.061 for TC reduction. The funnel plots of each of the above mentioned metrics showed an essentially symmetrical distribution pattern of the chromatic dispersion points, which were further analysed by Egger's test. The results all showed no significant publication bias (p > 0.05). In addition, although the reduction rate of PLA2R was p=0.005, after analysed by the cut-and-patch method, we considered that the possibility of publication bias was small.




Figure 6: Comparison-correction funnel plot of each outcome indicator

3.6 Adverse Reactions

The occurrence of adverse reactions was mentioned in 22 RCTs, of which 10 described the specific manifestations of adverse reactions in detail, mainly including infections, liver function abnormalities, gastrointestinal reactions, elevated blood pressure, blood glucose abnormalities and so on, and the patients were treated promptly and the subjects did not withdraw from the trial as a result. The occurrence of adverse reactions is shown in Table 3.

4. Discussion

A total of 35 studies were included in this paper, involving 2,518 IMN patients, of which 1,267 were in the experimental group and 1,251 were in the control group, and the differences between the experimental group and the control group in terms of gender and age were not statistically significant. A total of 5 types of interventions of Chinese medicine compound preparation + conventional western medicine were investigated in this paper, aiming to objectively assess their efficacy and effectiveness in clinical application. The data were analysed using a random-effects model, and the overall heterogeneity was low among all the included studies. The results showed that compared with other types of TCM compound preparations + conventional western drugs, the formula for tonifying deficiency, eliminating heat and stasis and dispelling dampness + conventional western drugs (SUCRA: 71.2%) was more effective in improving the overall clinical efficacy; the formula for tonifying deficiency, eliminating heat and stasis + conventional western drugs was more effective in lowering the quantitative 24-hour urinary protein (SUCRA: 95.3%) and total cholesterol (SUCRA: 98.2%); the formula for tonifying deficiency, eliminating heat and stasis and dispelling dampness + conventional for configure deficiency, eliminating heat and stasis and between drugs was more effective in lowering the formula for clearing heat and eliminating dampness + conventional Western drugs The formula for clearing heat and eliminating dampness + conventional western medicine ranked the highest in lowering blood creatinine (SUCRA: 80.4%) and increasing serum albumin level (SUCRA: 72.9%).

Based on the above results, we further explored in depth the therapeutic mechanism of various types of TCM compound formulas + conventional western drugs. The reason why the formulae of the category of tonifying deficiency, eliminating stasis and dispelling dampness + conventional western medicines could improve the overall clinical effectiveness rate may be related to the fact that the formulae of this category are more in line with the basic etiology and pathogenesis of IMN patients, i.e., deficiency of spleen and kidney qi coupled with the interconnection of dampness and stasis. Blood stasis and water stagnation are the cause and effect of the same source of fluid and blood, as mentioned in "The Essentials of the Golden Chamber", "When blood is not favourable, it becomes water." Clinical patients often present with dark skin colour, swelling of the lower limbs, skin ecchymosis, purple and dark tongue, white moss, and sunken and fine pulse. The formulas for tonifying deficiency, eliminating stasis and dispelling dampness included in this study, such as "Warming Yang and Passing the Lumps Formula", "Warming Yang and Dispelling Dampness and Passing the Lumps Formula" and "Strengthening the Spleen and Inducing Dampness Formula", are mostly based on the methods of benefiting qi, warming yang, inducing dampness and invigorating blood circulation and promoting circulation of blood. The most frequently used medicines include: Astragalus, Angelica sinensis, Salvia miltiorrhiza, leeches, Poria, motherwort, etc., to regulate Qi and blood and to treat blood and water at the same time. Huang Han medicine" has said: "astragalus can stretch the positive qi, back to the fluid, solid and dense coupling, then the stagnant water from the back down, urinary fluency, slippery skin and get moist", so the patients with this evidence mostly with large doses of astragalus with the application of qi, qi and blood, replenish the qi and water, modern pharmacological studies have shown that astragalus has an anti-oxidative stress, improve immunity, protection of renal tissues and other effects[52,53].In addition, Kun Xian capsule, which represents dispelling wind and removing dampness and activating blood circulation, can reduce foot cell damage and proteinuria level by inactivating β -catenin protein in mice with diabetic nephropathy, and inhibit disease progression [54].

Clinical findings show that IMN patients with predominantly deficiency evidence tend to have a long history of illness, recurrent and prolonged illness, with the most severe deficiency of the lungs, spleen and kidneys. The pathogenesis of the disease is mostly identified as deficiency of lung and kidney yin, lung and spleen qi, and spleen and kidney yang, and oedema, fatigue and proteinuria are common in the clinic. Zhang Jiebin of the Ming Dynasty mentioned in Class Classic - Treatment of Deficiency: "For Qi deficiency, it is appropriate to tonify its upper part; for essence deficiency, it is appropriate to tonify its lower part; for Yang deficiency, it is appropriate to tonify and warm at the same time; and for Yin deficiency are Chinese medicinal preparations represented by "Zhenwu Tang," "Ginseng Astragali and Dihuang Tang," and "Sijunzi Tang," with commonly used medicines including Codonopsis pilosulae, Astragalus membranaceus, Poria cocos, and Chinese yam, The commonly used herbs include Radix Astragali, Poria, Chinese yam, Radix Rehmanniae Praeparata, Cornus Officinalis, etc. These herbs tonify qi and

blood, nourish the spleen and kidneys, and help to correct the imbalance of qi and blood and the internal organs of patients with IMN from the perspective of "supporting the right side of the body". 70%—80% of patients with IMN are positive for the antibody to PLA2R, and most cross-sectional studies have shown that the high level of antibody to PLA2R Most cross-sectional studies have shown that high levels of PLA2R antibodies are one of the main reasons for the decrease in spontaneous remission rate, increase in disease activity and accelerated progressive loss of renal function in patients with IMN, and that lowering the titer of PLA2R antibodies as early as possible can help improve the long-term prognosis of patients [45-47]. Modern pharmacological studies have shown that deficiency tonic formulas have the effect of lowering urinary protein, reducing inflammatory factors and enhancing immunity [48,49]. However, there are few reports in the literature on the association between deficiency tonic formulae and PLA2R antibodies, which need to be further explored.

Deficiency and stasis are the most common clinical conditions in IMN patients. If there is deficiency in qi, the blood flow will not be smooth and the renal channels will be stagnant; if there is stagnation in blood, the deficiency will be even worse, which will lead to a vicious circle, and it usually manifests itself as thickening of the glomerular basement membrane or formation of tubular microthrombosis [50]. Clinical patients are mostly manifested as fatigue and lethargy, swelling of the face and limbs, and skin and nail mistakes. Wang Qingren in the Qing Dynasty in the "medical forest correction - on the wind is not the wind" cloud: yuan qi is weak, will not be able to reach the blood vessels, blood vessels without gas, will stay and stasis. Formulas for replenishing deficiency and eliminating stasis, such as "Benefiting Qi and Eliminating Crimes Formula", "Plus Flavour Tonic Yang Returning Five Soup", and "Ginseng Astragali and Di Huang Combined with Peach and Red Four Substances Soup", which were included in this study, are one of the best interventions for lowering TC and 24 hUTP, and have been used most frequently. The most frequently used drugs include: Astragalus, Codonopsis pilosula, Radix et rhizoma, Radix Rehmanniae Praeparata, Radix Angelicae Sinensis, Rhizoma Ligustici Chuanxiong, Radix et Rhizoma Polygoni Multiflori, Radix et Rhizoma Polygoni Multiflori, and so on, which benefit the qi and promote water retention, nourish and invigorate blood. Modern pharmacological studies have shown that such formulas not only help to increase renal blood flow and reduce podocyte damage, but also slow the progression of renal disease [44]. A retrospective clinical study based on 495 patients with IMN found that high levels of TC were positively associated with glomerular injury and increased urinary protein, and that improving lipid levels could help reduce urinary protein [51].

IMN patients with deficiency of both qi and yin, and interlocking of dampness and heat as the main evidence often show swollen face and limbs, soreness and weakness of waist and knees, redness and astringency of urine, foul-smelling breath, or skin boils, sores and ulcers, and so on. The Jingyue Encyclopaedia states, "For the disease of dampness-heat, it is appropriate to clear and benefit, and the heat goes away, so does the dampness." Most of the literature included in this study is based on the method of benefiting qi and nourishing yin, clearing heat and inducing dampness, such as "Benefiting qi and tonifying the kidneys to clear dampness" and "Strengthening the spleen and the kidneys to clear heat and induce dampness", etc. Commonly used medicines include: Astragalus, Cornu Cervi Pantotrichum, raspberry, Cuscuta chinensis, cypress, Plantago ovata, Poria cocos, and Jiexue cao. This formula benefits Qi and nourishes Yin, nourishes the liver and kidneys, and clears heat and relieves dampness. Modern pharmacological studies have shown that these medicines can reduce renal pathological damage by inhibiting endoplasmic reticulum stress and repairing foot cell damage, thus improving clinical efficacy [55,56].

IMN patients with multiple pathological factors such as deficiency, stasis, dampness and heat are mostly seen in the middle and late stages of the disease, which is often summarised by the TCM theory of "poisonous evil". Clinical manifestations include fatigue, oedema, urine and turbidity repeatedly, and the condition is stubborn and difficult to be cured; if the disease is prolonged, it will be caused by the deficiency, and become a syndrome of mixed deficiency and reality. The Political Parameters states, "Poisonous evils cannot enter without deficiency, and if the stomach qi is weak again, the poisonous evils will sink in, and the treatment will not cure the disease for years and months." The Chinese medicinal preparations included in this study, such as "Qi Di Ku Kidney Formula", "Huang Cu Yi Kidney Pill", and "Yi Qi, Dampness and Collaterals Soup", were mainly used to strengthen the spleen and the kidneys, and at the same time, they were also used to detoxify and relieve dampness, and to remove blood stasis and clear the collaterals. The most frequently used medicines include: Astragalus, Radix Rehmanniae Praeparata, Salviae Miltiorrhizae, Leeches, Radix et Rhizoma Alba, Zedoariae, etc. Modern pharmacological studies have shown that such formulas can help to reduce SCr levels, reduce the micro-inflammatory state of the kidneys, increase renal blood flow and delay the progression of chronic kidney disease [57,58].

	intervention measures	negative	reaction		
Author/year	in the test group	T C			
Xing Yang 2023	Jiawei Zhenwu Tang + CT	Not present	Not present		
Zhen Cai 2019	Radix Astragali Di Huang Tang + CT	-	-		
Lei Wang 2020	Radix Astragali Di Huang Tang + CT	-	-		
Chao Song 2020	Warming Yang and Lifting Water Formula +CT	Not present.	1 case of acute renal failure		
Ling Huang 2023	Yiyuanjianzhong Formula+CT	Not present.	Not present		
Jieqi Zheng 2019	Zhen Wu Tang with Angelica Sin ensis and Paeoniae Alba+CT	Failure to appear.	Not present		
Xueyan Sun 2022	Benefiting Qi, Nourishing Kidney and Promoting Blood+CT	Not present	Not present		
Xin Feng 2021	Benefiting Qi and Eliminating Cri mes+CT	Infection 3 cases, deep vein thrombosi s 1 case, and	Infection 10 cases, deep vein throm sis 5 cases, and		
Yating Zhang 2022	Radix Astragali Di Huang Tang+	3 cases of facial acne	Facial acne 12 cases		
	CT Oi Jishen combined with Taohon	Elevated blood sugar 8 cases, peptic ul	Elevated blood sugar 9 cases, peptic		
Guojun Tang 2020	g Siwu Decoction + CT Add flavour to tonify Yang and res	cer 3 cases, and Hypertension 9 cases, Infection 7 case	lcer 4 cases, and Hypertension 12 cases, Infection 16		
Chongxia Zhao 2022	tore the five elements+CT	S	ases		
Xue Li 2022	Invigorate Blood and Promote Wa ter Formula + CT	Acute kidney injury, 1 case.	Liver function abnormality 1 case		
Changan Chen 2022	Tonifying Qi and Benefiting Kidn ey Formula + CT	-Gastrointestinal symptoms	-Gastrointestinal reactions.		
Jiajiao Zuo 2018	Qiling Tongluo Prescription + C T	Gastrointestinal symptoms 2 cases	Digestive tract reaction 5 cases, urin y tract reaction 1 case		
Zhou Shi 2022	Benefiting Qi, Tonifying the Kid neys and Clearing the Profit For mula + CT	-Gastrointestinal symptoms.	-Lung infection 2, leukocyte reactio 1		
Jia Liu 2021	Strengthening the spleen, benefiti ng the kidneys, clearing heat and inducing dampness formula + C T	Digestive tract symptoms 2 cases	lung infection 2 cases, leukopenia 2 ases, and		
Yun Ma 2023	Warming Yang and Clearing Dampness Formula + CT	Not present	Gastrointestinal symptoms in 3 case abnormal liver function in 1 case		
Jie Li 2020	Wen Yang Dispels Dampness and Circulates Dampness For mula + CT	Not present	Not present		
Yanan Zhang 2023	Wen Yang Dispels Dampness and Circulates Dampness For mula + CT	Not present	Not present		
Qiang Liu 2019	Warming Yang, Promoting Bl ood and Lifting Water+CT	Liver function abnormalities 2, leukop enia 2, gastrointestinal reaction 1, infe ction 1	Not present		
Zheng Zhang 2022	Jin Qi Benefit Kidney Formul a+CT	Not present	Liver function abnormality 3 cases, ukopenia 10 cases, gastrointestinal action 7 cases, infection 5 cases		
Kexin Wang 2022	Ginseng Astragali and Dihuan	Not present	Not present		
Jianjun Guo 2022	g Tang+CT Strengthening the spleen and dispelling dampness+CT	Dizziness 1 case, nausea 1 case, diarrh oea 1 case	Not present		
Meng Ji 2021	Kun Xian Capsule±CT	Elevated blood sugar 2 cases, peptic ul cer 3 cases, and	Dizziness 2 cases, nausea 1 case, dia hoea 2 cases		
Jie Liu 2022	Rhizoma Ligustici Tongluo C apsule+CT	2 cases of hypertension, 1 case of infe ction	9 cases of elevated blood glucose, 4 ases of peptic ulcer, and		
Wu 2022	Strengthening the Spleen, Dis pelling Dampness and Hepato conjugate Formula+CT	Liver function abnormality 1 case, dig estive symptoms 2 cases	Hypertension 8 cases, infection 5 ca s		
Leilei He 2022	Kidney Yikang+CT	4 cases of menstrual disorders in wom en; 1 case of gastrointestinal reaction; 1 case of alanine aminotransferase ele vation	Liver function abnormality 3 cases, gestive symptoms 5 cases, lung infe ion 1 case, urinary tract infection 1 se		
Genping Lei 2019	Astragalus Di-Fixing Kidney Tablet+CT	-1 case of alanine aminotransferase ele vation	3 cases of gastrointestinal reactions: cases of abnormal liver function; 3 ses of abnormal glucose metabolism 2 cases of lung infection, 1 case of u nary tract infection; 1 case of venou hrombosis;		

Table 3: Occurrence of adverse reactions	Table 3:	ence o	Oc	adverse	reactions
--	----------	--------	----	---------	-----------

46

Huaxia Liu 2019	Tonifying the Kidneys, Resol ving Blood Stasis and Clearin g Drainage Formula + CT	Diarrhoea 2 cases	2 cases of new-onset hypertension
Lina Qiao 2020	Tonifying Qi, Resolving Dam pness and Clearing Drainage+ CT	Renal vein thrombosis 1 case	-
Jin Wu 2021	Radix Astragali and Radix Re hmanniae Formula+CT	Infection 1 case	3 cases of vomiting, 1 case of nausea, 2 cases of diarrhoea
Rong Zhao 2021	Huangtu Yi Kidney Granules +CT	Liver function abnormality 1 case, dru g-induced hyperglycaemia 2 cases	1 case of renal vein thrombosis, 0 cas es of deep vein thrombosis, and
Gaohua Ping 2021	Clearing and Resolving Turbi dities Capsule+CT	Not present	pulmonary embolism 1 case, renal fail ure 1 case
Yaping Guo 2021	Qi Di Tao Hirch Er Cicada Fo rmula+CT	-Not occurring	Infection 2 cases
Lv W2021	Nephritis Rehabilitation Table ts+CT	Not present	Liver function abnormality 1 case, dr ug-induced hyperglycaemia 4 cases

There are some limitations in this study: (1) the quality of the literature varies, and some studies did not describe the randomisation method and the allocation concealment scheme; (2) no direct comparison between TCM compound prescriptions was formed, which may have some errors; (3) no statistical comparison of drug dosages of similar prescriptions was performed, which may affect the authenticity of the results.

In conclusion, this study provides evidence-based medical evidence for the treatment of IMN through reticulated Meta-analysis, which can be used by clinicians to quickly select the most efficacious TCM compound formula with the best efficacy based on the clinical manifestations of IMN patients under the premise of evidence identification. However, there is some variability in the selection of drugs in the included studies, especially in the activation of blood circulation and elimination of blood stasis, which is affected by geographic factors or the personal medication habits of physicians, with large differences in the types and dosages of drugs, and it is recommended that clinicians can make lateral comparisons when selecting drugs in the future, so as to formulate the optimal formulas that are in line with the clinical indexes of patients with IMN. In addition, there is still a lack of high-quality, large-sample R-conventional western drugs in clinical studies of TCM, and it is hoped that research specifications can be further clarified and the quality of research can be improved in the future, so as to provide a higher level of evidence-based medical evidence for the treatment of IMN with TCM.

Acknowledgments

Supported by National Natural Science Foundation of China (82174335); Huang Dainian-style Teachers' Team in Universities in Shaanxi Province (Shaanxi Education Letter [2023] No. 668); Evidence-based Optimization Research on TCM Diagnosis and Treatment Protocols for Primary Membranous Nephropathy (2020XZ005).

References

- [1] SHANG R, ZHU Y J, LIN Z Y, et al. Comparison and clinical analysis of the variation of pathological types of primary glomerular diseases in Yu and Qiong[J]. Journal of Clinical Nephrology, 2021, 21(2):111-118.
- [2] VON GROOTE T C, WILLIAMS G, AU E H, et al. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome[J]. Cochrane Database Syst Rev, 2021, 11(11):Cd004293.
- [3] LANG R, WANG X, LIANG Y, et al. Research progress in the treatment of idiopathic membranous nephropathy using traditional Chinese medicine[J]. Transl Int Med, 2020, 8(1):3-8.
- [4] YANG L H, SU P L, BAO K. Clinical practice guideline for idiopathic membranous nephropathy in Chinese medicine (2021)[J]. Chinese Family Medicine, 2023, 26(6):647-659+645.
- [5] SADEGHIRAD B, FOROUTAN F, ZORATTI M J, et al. Theory and practice of bayesian and frequentist frameworks for network meta-analysis[J]. BMJ Evid Based Med, 2023, 28(3):204-209.
- [6] YANG L H, SU P L, BAO K. Clinical practice guideline for idiopathic membranous nephropathy in Chinese medicine (2021)[J]. Chinese Family Medicine, 2023, 26(6):647-659+645.
- [7] ROVIN B H, ADLER S G, BARRATT J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4):753-779.
- [8] LIU J C, LIU C, HUA C G. Interpretation of the randomised controlled trial risk of bias evaluation tool RoB2 (2019 revision)[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21(6):737-744.
- [9] YANG X. Clinical efficacy evaluation of adding flavour Zhenwu Tang in treating patients with idiopathic membranous nephropathy of spleen and kidney yang deficiency type[D]; Anhui University of Traditional Chinese Medicine, 2023.

- [10] CAI Q, WANG L, ZHAO W J. Observation on the therapeutic effect of 32 cases of idiopathic membranous nephropathy with qi and yin deficiency type treated with ginseng astragali dihuang soup[J]. Beijing Traditional Chinese Medicine, 2019, 38(10):1029-1032.
- [11] WANG L, ZHAO W J, ZHAO J, et al. Clinical study on the treatment of M-type phospholipase A2 receptor antibody-positive idiopathic membranous nephropathy with ginseng qi dihuang tang[J]. Hebei Traditional Chinese Medicine, 2020, 42(4):522-527.
- [12] SONG C. Observation on the efficacy of Wen Yang Li Shui Fang in treating early idiopathic membranous nephropathy and its effect on anti-PLA2R antibody[D]; Guangzhou University of Traditional Chinese Medicine, 2020.
- [13] LEI G P, ZHU K R, HU L F, et al. Effect of QiDiGu Kidney tablets on anti-M-type phospholipase A2 antibodies in patients with idiopathic membranous nephropathy with deficiency of qi and yin a prospective randomised controlled clinical study[J]. Chinese Journal of Integrative Nephrology, 2019, 20.
- [14] HUANG L. Intervention study of qi deficiency idiopathic membranous nephropathy in remission based on Chinese medicine physique adjustable theory using Yiyuanjianzhongfang[D]; Fujian University of Traditional Chinese Medicine, 2023.
- [15] ZHAO C X, LIU X C, GUO Y P. Effect of Jiawei tonifying Yang and returning five soup combined with tacrolimus in the treatment of idiopathic membranous nephropathy with qi deficiency and blood stasis and its effect on coagulation fibrinolytic function, PLA2R, and THSD7A levels[J]. Clinical Medicine Research and Practice, 2022, 7(26).
- [16] LAI X. Clinical observation on the effect of blood activation and water-inducing formula on clinical efficacy and serum anti-PLA2R antibody in patients with idiopathic membranous nephropathy with Yang deficiency and blood stasis[D]; Guangxi University of Traditional Chinese Medicine, 2023.
- [17] SHI Z. Clinical observation on the treatment of idiopathic membranous nephropathy with deficiency of qi and yin and dampness-heat type by Yiqi, tonifying the kidney and clearing the li formula[D]; Shandong University of Traditional Chinese Medicine, 2022.
- [18] LIU J. Clinical study on the treatment of idiopathic membranous nephropathy by strengthening the spleen and benefiting the kidney, clearing heat and inducing dampness[D]; Changchun University of Traditional Chinese Medicine, 2021.
- [19] LIU H X. Clinical study on the treatment of idiopathic membranous nephropathy by tonifying the kidney, resolving stasis and clearing drainage and the effect on serum anti-PLA2R antibody[D]; Shandong University of Traditional Chinese Medicine, 2019.
- [20] QIAO L. Clinical study on the treatment of spleen and kidney qi deficiency and damp-heat stasis in idiopathic membranous nephropathy with Yiqi, Huaqi and Tongluo Tang[D]; Shandong University of Traditional Chinese Medicine, 2020.
- [21] MA Y, TONG X Q, MA E W, et al. Clinical study on the treatment of idiopathic membranous nephropathy with spleen and kidney yang deficiency and rheumatism and stasis paralysis by combination of Wen Yang Tongluo Formula and non-immunosuppression[J]. Hebei Traditional Chinese Medicine, 2023, 45.
- [22] LI J, MA E, ZHU X T, et al. Clinical efficacy study on the treatment of idiopathic membranous nephropathy by warming yang, dispelling dampness and clearing collaterals formula[J]. Journal of Hebei Traditional Chinese Medicine, 2020, 35(1).
- [23] ZHANG Y. Clinical observation and network pharmacological research on the treatment of idiopathic membranous nephropathy with warm-yang, dampness dispelling and channelisation formula[D]; Hebei College of Traditional Chinese Medicine, 2023.
- [24] QIANG L, XUE X, CHENG H, et al. Treatment of idiopathic membranous nephropathy by warming yang, activating blood and promoting water[J]. Journal of Chinese Medicine, 2019, 34(10):2231-2235.
- [25] WU J, WANG T, WANG Z X, et al. Effectiveness of Qi Di Ku Ren Formula in treating patients with idiopathic membranous nephropathy and its effect on laboratory indexes[J]. Clinical Medicine Research and Practice, 2021, 6(14).
- [26] ZHANG Z. Investigation on the effect of Jinqi Yi Kidney Formula in treating patients with idiopathic membranous nephropathy (kidney deficiency and dampness stasis)[J]. Electronic Journal of Modern Medicine and Health Research, 2022, 6(14).
- [27] WANG K X. Clinical observation on the treatment of idiopathic membranous nephropathy with spleen and kidney deficiency and dampness and blood stasis type by adding ginseng and astragalus dihuang soup[D]; Heilongjiang Academy of Traditional Chinese Medicine, 2023.
- [28] CHEN C Y, ZHANG J, CAI H Y. Clinical observation on the treatment of membranous nephropathy with qi deficiency and blood stasis certificate by replenishing qi and benefiting kidney formula and its effect on PCX and PLA2R[J]. Medicine and Health, 2022,(11):0016-0020.

- [29] ZHAO R. Clinical study on the effect of Huangtu Yi kidney granules on Th17/Treg immune imbalance in patients with idiopathic membranous nephropathy[D]; Shaanxi University of Traditional Chinese Medicine, 2021.
- [30] GUO J J, LI J, WANG X L, et al. Effectiveness of spleen-strengthening and dampness-dispelling method combined with cyclophosphamide in the treatment of idiopathic membranous nephropathy (qi deficiency, blood stasis and dampness entrapment) and its modulating effect on Cys C and anti-PLA2R levels[J]. China Medical Innovation, 2022, 19(25).
- [31] JIEQI Z. Clinical observation of Zhenwu Tang combined with Angelica sinensis and Paeonia lactiflora powder in the treatment of idiopathic membranous nephropathy and the effect of anti-PLA2R antibody[D]; Fujian University of Traditional Chinese Medicine, 2019.
- [32] SUN X, WANG Y F, CAI Q, et al. Treatment of 42 cases of idiopathic membranous nephropathy by Yiqi nourishing kidney and activating blood formula[J]. Global Chinese Medicine, 2022, 15(7):1264-1268.
- [33] FENG X. Observation on clinical efficacy of Yiqi and elimination of symptoms of primary membranous nephropathy I-II stage of qi deficiency and blood stasis type by Yiqi and elimination of symptoms of primary membranous nephropathy formula[D]; Shanxi University of Traditional Chinese Medicine, 2021.
- [34] ZHANG Y T. Clinical observation on the treatment of membranous nephropathy of qi and yin deficiency and blood stasis type by adding and subtracting formula of ginseng qi di huang tang combined with tacrolimus[D]; Shandong University of Traditional Chinese Medicine, 2022.
- [35] TANG G J. Clinical study on the treatment of idiopathic membranous nephropathy by ginseng qi di huang combined with peach red four things soup and the effect on serum anti-PLA2R antibody[D]; Shandong University of Traditional Chinese Medicine, 2020.
- [36] PING G H, YANG W, GAO G, et al. Clinical observation on the treatment of idiopathic membranous nephropathy with damp-heat stasis evidence by clearing and resolving turbid capsule[J]. Chinese Folk Therapy, 2022, 30(12):57-60.
- [37] JI M, MA Y Y, GUO D S, et al. Comparison of efficacy of Kunxian capsule and tacrolimus in the treatment of idiopathic membranous nephropathy[J]. Journal of Xinxiang Medical College, 2021, 38(5):472-476.
- [38] GUO Y, GUO T L, LIU X Q, et al. Effects of Qi Di Tao Hiru Er Cicada formula combined with tacrolimus on CD4~+, CD8~+ and urine protein quantification in patients with membranous nephropathy[J]. Clinical Medicine Research and Practice, 2021, 6(2):129-131.
- [39] ZUO J J, ZHAO Z, SUN R, et al. Clinical observation on the treatment of high-risk patients with idiopathic membranous nephropathy in combination with methylprednisolone and cyclophosphamide by Qi Ling Tongluo Formula[J]. Chinese Journal of Traditional Chinese Medicine, 2018, 36(11):2723-2725.
- [40] HE L L. Evaluation of the efficacy of renyikang on the prevention and treatment of complications of idiopathic membranous nephropathy and the study of the mechanism of action[J]. Heilongjiang Medicine, 2022, 46(21).
- [41] LIU J, ZHONG J Y, ZHU Z Z. Clinical effect of Rhizoma Ligustici Tongluo Capsule in the treatment of patients with blood stasis and blood obstruction type membranous nephropathy and its effect on serum anti-PLA2R antibody level[J]. Guangxi Medicine, 2022, 44.
- [42] LV W, WANG M R, ZHANG C Z, et al. Effect of nephritis rehabilitation tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy[J]. World J Clin Cases, 2021, 9(34):10464-10471.
- [43] WU K, YIN H, DU A. Effects of modified Jianpi Qushi Heluo Decoction on scores of TCM syndromes, 24 h urinary albumin, and plasma albumin in IMN of spleen-kidney qi deficiency[J]. Emerg Med Int, 2022, 2022:6061709.
- [44] TIAN R, WANG L, CHEN A, et al. Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NF-kB[J]. Biomed Pharmacother, 2019, 115:108904.
- [45] TIMMERMANS S A, ABDUL HAMID M A, COHEN TERVAERT J W, et al. Anti-PLA2R antibodies as a prognostic factor in PLA2R-related membranous nephropathy[J]. Am J Nephrol, 2015, 42(1):70-77.
- [46] KANIGICHERLA D, GUMMADOVA J, MCKENZIE E A, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy[J]. Kidney Int, 2013, 83(5):940-948.
- [47] MAHMUD M, PINNSCHMIDT H O, REINHARD L, et al. Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy[J]. PLoS ONE, 2019, 14(9):e0221293.
- [48] LI H, LU R, PANG Y, et al. Zhen-Wu-Tang protects IGA nephropathy in rats by regulating exosomes to inhibit NF-KB/NLRP3 pathway[J]. Front Pharmacol, 2020, 11:1080.
- [49] TIAN Z, WANG B L, ZHANG L Q. Clinical study on the treatment of chronic kidney disease (stage III-IV) with Jiawei Zhenwu Tang[J]. Journal of Chinese Medicine, 2017, 32(9):1757-1760.

- [50] GUO C, LI S, RAO X R. New goals and strategies of Chinese Medicine in prevention and treatment of chronic kidney disease[J]. Chin J Integr Med, 2019, 25(3):163-167.
- [51] DONG L, LI Y Q, GUO S M, et al. Hypercholesterolemia correlates with glomerular phospholipase A2 receptor deposit and serum anti-phospholipase A2 receptor antibody and predicts proteinuria outcome in idiopathic membranous nephropathy[J]. Front Immunol, 2022, 13:905930.
- [52] WANG J, GUO H M. Astragaloside IV ameliorates high glucose-induced HK-2 cell apoptosis and oxidative stress by regulating the Nrf2/ARE signaling pathway[J]. Exp Ther Med, 2019, 17(6):4409-4416.
- [53] CAO Y, ZHANG L, WANG Y, et al. Astragaloside IV attenuates renal fibrosis through repressing epithelialto-mesenchymal transition by inhibiting microRNA-192 expression: In vivo and in vitro studies[J]. Am J Transl Res, 2019, 11(8):5029-5038.
- [54] JIN B, LIU J, ZHU Y, et al. Kunxian capsule alleviates podocyte injury and proteinuria by inactivating βcatenin in db/db mice[J]. Front Med (Lausanne), 2023, 10:1213191.
- [55] YANG L P, LIU Y M, ZHAN Y L, et al. Effect of Yiqi Qinghe Cream on the expression of Wnt/β-catenin signalling pathway in renal tissues of an aminonucleoside puromycin rat model of nephrotic syndrome[J]. Chinese Journal of Traditional Chinese Medicine, 2021, 36(08):5029-5032.
- [56] YANG L P, LIU Y M, ZHAN Y L, et al. Mechanism study on the protection of aminonucleoside puromycin rat model of podocyte injury through endoplasmic reticulum stress pathway by Yiqi Qinghe Cream[J]. Chinese Journal of Integrative Nephrology, 2016, 17(08):667-671.
- [57] ZHENG Y, WANG N S, LIU Y N, et al. Effects of Niaoduqing particles on delaying progression of renal dysfunction: a post-trial, open-label, follow-up study[J]. Chin J Integr Med, 2019, 25(3):168-174.
- [58] ZHENG Y, CAI G Y, HE L Q, et al. Efficacy and safety of Niaoduqing particles for delaying moderate-tosevere renal dysfunction:a randomized, double-blind, placebo-controlled, multicenter clinical study[J]. Chin Med J (Engl), 2017, 130(20):2402-2409.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of Woody International Publish Limited and/or the editor(s). Woody International Publish Limited and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.